The biotechnology company Captozyme is spearheading an innovative approach to nutrition to prevent the formation of painful kidney stones and other complications arising from the absorption of calcium oxalate from food. The company’s research efforts are led by Dr Qing-Shan Li, co-founder and CSO of the company.
Captozyme was one of 20 companies selected to participate in the 2017 Florida Venture Capital Conference, out of the more than 100 companies that applied to be a part of the weekend-long event.
Captozyme Inc., a biotechnology company based in Gainesville, FL, recently raised $3.4 million. Captozyme plans to invest this money into the manufacturing and launch of Nephure, an oxalate-degrading enzyme to facilitate a low-oxalate diet.
Since opening in 2010, the Innovation Hub has helped launch 61 companies that created 763 jobs and lured more than $50 million in private investment.